The Advanced Therapies Network (ATN) aims to support networking opportunities and knowledge exchange between academic organisations, life sciences companies and investors in this area.
Estimated to have a global market worth of £9bn to 14bn by 2025, advanced therapies is a novel approach to medicine that uses experimental techniques to treat a wide range of conditions, including cancer and rare diseases.
There are over 130 advanced therapies companies in the UK, with 60% residing in the greater south east of England, including university spinouts such as Orchard Therapeutics, Autolus, Cell Medica, GammaDelta Therapeutics and Quethera.
Aims of the Advanced Therapies Network
The Advanced Therapies Network was launched in November 2018. Part of London Advanced Therapies and funded by the Research England, it brings together collective expertise in this area to accelerate the progression for patient benefit.
The ATN is running a series of events to discuss the challenges to commercialisation in the sector and provide networking opportunities. The events cover subjects such as clinical trials, investment, data and reimboursement.
Those from academia, NHS, government bodies, charities and companies who are offering supporting services around R&D activities can join the Network for free. Companies who provide services to advanced therapies companies are welcome to join the Network for a nominal annual fee (professional services membership). Become a member today and take advantage of events and networking opportunities in the advanced therapies space.
London Advanced Therapies
The recently established London Advanced Therapies (LAT) brings together the London scientific community working in the field of cell and gene-based therapies. Funded by Research England, and led by King’s College London, Imperial College London and University College London, LAT aims to catalyse London’s capabilities and outputs in the area of Advanced Therapies, through fostering collaborative work, facilitating commercial partnerships and creating a microclimate for innovation.
Confidence in Collaboration
A funding scheme designed to initiate new collaborations between London-based Colleges;
Collaborate to Innovate round 2:
A funding scheme to foster and support collaborative projects between commercial partners (SMEs) and academic research groups based in London who are working in advanced therapies;
Activities to map the landscape
Of expertise and research capabilities in London;
Design of educational programmes
To train the next generation of workforce relevant to developing and delivering gene and cell therapy products.